Physician profile
Mahyar Eidgah
NPI 1710023601
$76,209.49
in general payments reported to CMS, 2019-2025
52 companies · $27K in 2025
The $27K reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,785 · 2020: $4,074 · 2021: $4,416 · 2022: $4,160 · 2023: $15K · 2024: $17K · 2025: $27K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $35K · Food and Beverage: $16K · Travel and Lodging: $4,737 · Consulting Fee: $3,560.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $35,370.00 |
| Food and Beverage | $16,106.80 |
| Travel and Lodging | $4,737.12 |
| Consulting Fee | $3,560.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $49,478.27 | 2019-2025 | Descovy, Yeztugo, Biktarvy |
| Astrazeneca Pharmaceuticals LP | $6,051.41 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $3,998.00 | 2019-2025 | Jardiance |
| Abbvie INC. | $3,990.29 | 2021-2025 | |
| Lilly USA, LLC | $1,367.32 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Sanofi-Aventis U.S. LLC | $1,257.43 | 2019-2025 | |
| Corium, LLC | $1,157.08 | 2022-2025 | Azstarys |
| Glaxosmithkline, LLC. | $1,070.42 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Neos Therapeutics, LP | $810.15 | 2020-2024 | Adzenys Xr-Odt |
| Axsome Therapeutics, INC. | $801.82 | 2024-2025 | Auvelity |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $750.56 | 2019-2024 | Xifaxan, Trulance |
| Takeda Pharmaceuticals U.S.A., INC. | $547.97 | 2019-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $467.55 | 2024-2025 | Caplyta |
| Viiv Healthcare Company | $407.81 | 2022-2025 | Apretude |
| Bausch Health US, LLC | $339.80 | 2020-2023 | Aplenzin, Wellbutrin |
Show all 52 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mahyar Eidgah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.